Antiretroviral Drug Exposures Reported to Texas Poison Centers

向德克萨斯州中毒控制中心报告的抗逆转录病毒药物暴露事件

阅读:1

Abstract

Background. A number of different antiretroviral drugs are used to manage patients with human immunodeficiency virus (HIV). Objective. This study describes antiretroviral drug exposures reported to a large statewide poison center system. Methods. Cases were all antiretroviral drug exposures reported to the Texas Poison Center Network during 2000 to 2014. The distribution of cases was determined for various demographic and clinical factors. Results. Of a total of 632 exposures, the most commonly reported drugs were emtricitabine-tenofovir combination (17.1%), efavirenz-emtricitabine-tenofovir combination (13.8%), ritonavir (10.9%), lamivudine-zidovudine combination (10.3%), and efavirenz (10.1%). The annual number of antiretroviral drug exposures increased from 34 in 2000 to 67 in 2014. Males comprised 67.9% of the patients; 72.2% were 20 years or older. The exposures were 58.5% unintentional and 37.5% intentional. Only antiretroviral drugs were reported in 440 of the exposures. Of these exposures, 62.5% were managed on site, 28.0% were already at or en route to a health care facility when the poison center was contacted, and 8.6% were referred to a health care facility. The exposures were not serious in 88.7% of these cases. The most frequently reported adverse clinical effects were vomiting (5.7%), nausea (4.8%), dizziness/vertigo (3.2%), and drowsiness/lethargy (3.2%). Conclusions. The most commonly reported antiretroviral drugs were emtricitabine-tenofovir combination and efavirenz-emtricitabine-tenofovir combination. The patients were most likely to be adults and males. The exposures tended to be unintentional. Of those exposures involving only antiretroviral drugs, the majority of the exposures were not serious and could be managed outside of a health care facility.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。